EXODERIL CREAM 1% 15G
EXODERIL CREAM 1% 15G
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Mechanism of action
- antifungal drug for external use from the group of allylamines. The mechanism of action is associated with inhibition of ergosterol synthesis.
Naftifine has activity against dermatophytes such as the fungus of the genus Trichophyton, epidermophyte and microsporum, yeast fungi (Aspergillus species) and other fungi (for example, Sporotrix Schencki). In relation to dermatophytes and Aspergillus, naftifine acts fungicide in vitro. In relation to yeast, the drug exhibits fungicidal and fungistatic activity depending on the strain of the microorganism. In addition to the antifungal effect, naftifine has antibacterial activity against various gram-positive and gram-negative pathogens, which are often found in combination with fungal infections.
In clinical conditions, it was found that naftifine has an anti-inflammatory effect, which contributes to the rapid disappearance of the symptoms of inflammation, especially itching.
Since EXODERYL penetrates the skin quickly, creating stable antifungal concentrations in its various layers, it is possible to use it topically once a day.
Indications and usage
Exoderil used in the treatment of the following diseases:
- fungal infections of the skin and skin folds (tinea corporis, tinea inquinalis);
- interdigital mycosis (tinea manum, tinea pedum);
- fungal infections of the nails (onychomycosis);
- skin candidiasis;
- pityriasis lichen;
- inflammatory dermatomycosis (with or without itching).
Exoderil in the form of a solution for external use is effective in the treatment of mycoses affecting areas of the skin with hyperkeratosis, as well as having hair.
Hypersensitivity to naftifine or benzyl alcohol (preservative).
application and dose
Only for topical application to the skin or nails.
Exoderil should be applied to the affected skin surface and adjacent areas once a day after thorough cleaning and drying. To prevent recurrence of infection, therapy should be carried out for at least two weeks after a clinical cure is achieved. The duration of treatment varies from 2 weeks to 6 months.
In some cases, there may be signs of local inflammation, such as dry skin, redness or burning. Side effects are always reversible and do not require discontinuation of treatment.
Pregnancy and breastfeeding
Provided correct use of the drug on the fetus or a newborn child is unlikely. The results of teratogenicity studies do not indicate any embryotoxic action of naftifine.
WITH caution the drug should be used in children.
Avoid contact with eyes.
Topical solution should not be applied to the wound surface.
List B. The drug should be kept out of the reach of children at a temperature not higher than 30 ° C.